Pires Investments (PIRI), the investment company focused on next generation technology, updated in relation to Buymie, Ireland’s same-day grocery delivery company, an investment within the Sure Valley Ventures portfolio.
Zak Mir takes a charting perspective on some of the most followed London small caps. Today’s selection includes Audioboom, Beowulf, Canadian, Europa, Egdon, Eve, Genedrive, Kibo, Mosman, Mast, Powerhouse, Synairgen,
Omega (ODX), the specialist medical diagnostics company, said that it has raised gross proceeds of £5.0 million. It also proposes to raise up to an additional £2.0 million.
Oracle Power (ORCP), the international natural resources project developer, said that the drill programme over five geochemical target areas is underway at its 100% owned Jundee East Gold Project, located
Zak Mir takes a charting perspective on some of the most followed London small caps. Today’s selection includes 7Digital, 88 Energy, Active, Beowulf, Deltex, Europa, Global, Helium, Hargreaves, Revolution, Technology,
Zak Mir charts some of the most followed London small caps. Today’s selection includes Avacta, ARC, Beowulf, DeepVerge, Eurasia, Eco, Falcon, Guild, Prospex, United Oil and Gas, Xtract, Zanaga.
Zak Mir reviews the best-rising stocks covered in his daily technical analysis video over the past 12 months and looks at what they might do in 2022. The selection features
Another day, another contract win from Open Orphan (ORPH), the specialist contract research organisation and vaccine and antiviral testing company using human challenge clinical trials. It announced that hVIVO, a
Zak Mir takes a charting perspective to some of the most followed small caps on the London market. Today’s selection includes Abingdon, Seraphine, Beowulf, Bezant, Catenae, Getech, Galileo, Genedrive, Nanosynth,
Zak Mir takes a charting perspective to some of the most followed small-cap stocks on the London market. Today’s selection includes Atlantic Lithium, Beowulf, Belluscura, Catenae, Equals, Future, Ironveld, Novacyt,
It looks as though things are progressing faster than anticipated at OKYO Pharma (OKYO), the biotechnology company focused on dry eye diseases and ocular pain.
